Seikagaku’s Pain Drug May Need More Tailored Indication, REMS For Approval

 
• By Sarah Karlin-Smith
  
older woman cringing with lower back, leg pain
The FDA may narrow the patient population and limit treatment sites for Seikagaku's leg pain drug. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Product Reviews